Eagle Pharmaceuticals Stock Discussion

$Eagle Pharmaceuticals (EGRX.US)$ what happen... so sudden

$Eagle Pharmaceuticals (EGRX.US)$
Eagle Pharmaceuticals (Nasdaq: EGRX) received a delisting notification from Nasdaq on August 21, 2024, due to its failure to timely file the Q2 2024 Form 10-Q. This follows a previous notice on August 1, 2024, where Nasdaq granted the company continued listing subject to specific conditions. Eagle must file its 2023 Annual Report by September 30, 2024, and both Q1 and Q2 2024 Form 10-Qs ...

$Eagle Pharmaceuticals (EGRX.US)$
NEWS
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting

$Eagle Pharmaceuticals (EGRX.US)$
NEWS
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that data from the Company’s Phase III trial demonstrating the su...

Gapping up
In reaction to earnings/guidance:
• $PepsiCo (PEP.US)$+2.8%, $E2open Parent (ETWO.US)$ +0.7%
Other news:
• $Cango (CANG.US)$ +23.5% (approves special dividend of $0.50 per ordinary share or $1 per ADS)
• $El Pollo Loco (LOCO.US)$ +12.7% (declares $1.50/sh special div; also authorizes new $20 mln share repurchase program)
• $KnowBe4 (KNBE.US)$ +11.4% (KnowBe4 is close to a deal to be acquired by Vista Equity Partners according to ...

$SeaChange International (SEAC.US)$
- SeaChange Soars On Triller Merger Speculation, Trump Ties. stock breaking out.
$BLU
- BELLUS Health Stock Surges After Positive Data From Refractory Chronic Cough Trial. Stock almost hit double digits. Looking for break of $9
$Sigmatron International (SGMA.US)$
- ON Friday Company reported  Q2 EPS $0.69 Up From $0.15 YoY, Sales $100.20M Up From $69.62M YoY.  needs to hold $13 support level
$Eagle Pharmaceuticals (EGRX.US)$
- Eagle is seeking approval for a generic version of Vasostrict, which is marketed by (ENDP) Par unit and had total U.S. sales of $786 million in 2020.
$Lucid Group (LCID.US)$
- stock bouncing off $35 support as expected. Looking for break of $40 to keep moving higher.

$Sigmatron International (SGMA.US)$
- ON Friday Company reported  Q2 EPS $0.69 Up From $0.15 YoY, Sales $100.20M Up From $69.62M YoY. Up 100% for the day after hours. Looking to join on early market trend.
$Eagle Pharmaceuticals (EGRX.US)$
- Eagle is seeking approval for a generic version of Vasostrict, which is marketed by (ENDP) Par unit and had total U.S. sales of $786 million in 2020.
$SentinelOne (S.US)$
- stock getting multiple price target upgrades on wednesday. Hitting $50 plus as expected looking for more.
$Lucid Group (LCID.US)$
- Stock has support at $35. If holds we can see it reverse higher or back down $33 levels.
$QuantumScape (QS.US)$
- stock is near the support area of  $24. If held we can see a reversal to $25 plus or more.

$Sigmatron International (SGMA.US)$ - ON Friday Company reported  Q2 EPS $0.69 Up From $0.15 YoY, Sales $100.20M Up From $69.62M YoY. Up 100% for the day after hours. Looking to join on early market trend.
$Eagle Pharmaceuticals (EGRX.US)$ - Eagle is seeking approval for a generic version of Vasostrict, which is marketed by (ENDP) Par unit and had total U.S. sales of $786 million in 2020.
$SentinelOne (S.US)$ - stock getting multiple price target upgrades on wednesday. Hitting $50 plus as expected looking for more.
$Lucid Group (LCID.US)$ - Stock has support at $35. If holds we can see it reverse higher or back down $33 levels.
$QuantumScape (QS.US)$ - stock is near the support area of  $24. If held we can see a reversal to $25 plus or more.